Key points are not available for this paper at this time.
The majority of patients with metastatic renal cancer (mRC) experience reduced renal mass (RRM) prior to starting systemic anticancer treatment (SAT) due to the local burden of the primary tumor and/or local treatment. Patients who have undergone local treatment for renal carcinoma are at increased risk for acute kidney injury (AKI) and for the progression of chronic kidney disease. A percutaneous renal biopsy (PRB), which is relatively contraindicated in patients with a solitary kidney (SK), serves as a reference method for assessing renal toxicity.
Milanez et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: